TY - JOUR
T1 - Detection of flt3 gene mutations in patients with acute myeloid leukemia in surabaya, indonesia
T2 - A single-center study
AU - Budiono, Notopuro Paulus
AU - Jusak, Nugraha
AU - Harianto, Notopuro
N1 - Funding Information:
This work was supported by Faculty of Medicine, Airlangga University Support Grant under The Rector’s Directive Number 886/UN3/2018.
Publisher Copyright:
© 2020, Iranian Pediatric Hematology and Oncology Society. All rights reserved.
PY - 2020/6
Y1 - 2020/6
N2 - Background: FLT3 gene mutation contributes worse prognosis in patients with acute myeloid leukemia (AML). Almost 67% of patients with AML with FLT3 gene mutation cannot reach complete remission after induction therapy, and they are also at high risk of relapse. We aimed to investigate the FLT3-ITD,-TKD (D835) gene mutation prevalence in patients with AML at Surabaya and their association with leukocyte and bone marrow blast cell count. Methods: 20 de novo patients with AML were recruited during February–July 2018. They were investigated through routine AML check-up and detection for FLT3-ITD,-TKD (D835) gene mutation. Results: Four patients with de novo AML (20%) had FLT3-ITD gene mutation, and one patient had FLT3-TKD (D835) gene mutation. Median leukocyte count in patients with AML with FLT3-ITD mutation was higher than wild type patients ( 146.3×103/ µL vs 16.4 x 103 / µL, P=0,002). The mean bone marrow blast cell count was higher in patients with AML with FLT3-ITD mutation than wild type patients ( 86.5% vs 57.9%, P=0,047). The difference in leukocyte and bone marrow blast cell count in patients with FLT3-TKD (D835) mutation could not be analyzed since there was only one patient with this mutation. Conclusion: The prevalence of FLT3-ITD gene mutation in patients in AML in Surabaya was 20% and FLT3-TKD (D835) was 5%. Patients with FLT3-ITD gene mutation was associated with leukocyte and bone marrow blast cell count.
AB - Background: FLT3 gene mutation contributes worse prognosis in patients with acute myeloid leukemia (AML). Almost 67% of patients with AML with FLT3 gene mutation cannot reach complete remission after induction therapy, and they are also at high risk of relapse. We aimed to investigate the FLT3-ITD,-TKD (D835) gene mutation prevalence in patients with AML at Surabaya and their association with leukocyte and bone marrow blast cell count. Methods: 20 de novo patients with AML were recruited during February–July 2018. They were investigated through routine AML check-up and detection for FLT3-ITD,-TKD (D835) gene mutation. Results: Four patients with de novo AML (20%) had FLT3-ITD gene mutation, and one patient had FLT3-TKD (D835) gene mutation. Median leukocyte count in patients with AML with FLT3-ITD mutation was higher than wild type patients ( 146.3×103/ µL vs 16.4 x 103 / µL, P=0,002). The mean bone marrow blast cell count was higher in patients with AML with FLT3-ITD mutation than wild type patients ( 86.5% vs 57.9%, P=0,047). The difference in leukocyte and bone marrow blast cell count in patients with FLT3-TKD (D835) mutation could not be analyzed since there was only one patient with this mutation. Conclusion: The prevalence of FLT3-ITD gene mutation in patients in AML in Surabaya was 20% and FLT3-TKD (D835) was 5%. Patients with FLT3-ITD gene mutation was associated with leukocyte and bone marrow blast cell count.
KW - Acute myeloid leukemia
KW - Blast count
KW - FLT3-ITD
KW - FLT3-TKD (D835)
KW - Leukocyte
UR - http://www.scopus.com/inward/record.url?scp=85089586764&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85089586764
SN - 2008-4595
VL - 12
SP - 54
EP - 57
JO - Iranian Journal of Blood and Cancer
JF - Iranian Journal of Blood and Cancer
IS - 2
ER -